The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer-Reference-Cited by-同舟云学术

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

Published:2015-04 Issue:4 Volume:23 Page:717-727
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Fujita Yu,Yagishita Shigehiro,Hagiwara Keitaro,Yoshioka Yusuke,Kosaka Nobuyoshi,Takeshita Fumitaka,Fujiwara Tomohiro,Tsuta Koji,Nokihara Hiroshi,Tamura Tomohide,Asamura Hisao,Kawaishi Makoto,Kuwano Kazuyoshi,Ochiya Takahiro

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference31 articles.

1. Lung cancer: new biological insights and recent therapeutic advances;Ramalingam;CA Cancer J Clin,2011

2. MicroRNA control of signal transduction;Inui;Nat Rev Mol Cell Biol,2010

3. Applications of microRNAs in the diagnosis and prognosis of lung cancer;Shen;Expert Opin Med Diagn,2012

4. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

5. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm;Current Gene Therapy;2025-04

2. Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?;Cells;2024-06-20

3. Exploring Natural Compounds Targeting PD-L1 and STAT3: Toxicogenomic Analysis, Virtual Screening, Molecular Docking, ADMET Evaluation, and Biological Activity Prediction;Current Computer-Aided Drug Design;2024-05-28

4. MiR-134-5p inhibits the malignant phenotypes of osteosarcoma via ITGB1/MMP2/PI3K/Akt pathway;Cell Death Discovery;2024-04-25

5. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways;Cancer Cell International;2024-03-10